ADHD Medications: Risk, Bias, and Real Outcomes
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
ADHD Medications: Risk, Bias, and Real Outcomes
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Title: ADHD Medications: Risk, Bias, and Real Outcomes
Hosts: James Kennedy, PMHNP-BC & Jon Murphy, PMHNP-BC
In this first episode of Compass Point Institute, James and Jon break down a major new study published in JAMA Psychiatry (June 25, 2025) tracking ADHD medication outcomes in over 260,000 individuals.
🎯 Topics covered:
- Key findings from a 15-year longitudinal study
- Reduced self-harm, accident, and criminal risk
- Navigating stigma, DEA scrutiny, and Schedule II status
- Provider bias and the myth of “weekend breaks”
- Practical clinical guidance on stimulant prescribing
- The difference between physiological vs psychological addiction
This episode is designed to support mental health clinicians with real-world data, clear context, and grounded insight.
📬 Have a topic you want us to cover? Reach out anytime.
🧭 Compass Point Institute — Empowering the next generation of mental health clinicians.
Ce que les auditeurs disent de ADHD Medications: Risk, Bias, and Real Outcomes
Moyenne des évaluations de clientsÉvaluations – Cliquez sur les onglets pour changer la source des évaluations.
Il n'y a pas encore de critiques pour ce titre.